10 results
• To estimate the difference in the efficacy and safety of RAD001 10 mg p.o. daily dose in combination with bevacizumab 10 mg/kg administered intravenously every two weeks for first-line treatment of patients with metastatic carcinoma of the kidney…
To assess angiographic and clinical outcomes after treatment of ISR of a prior BMS in the native coronary system with the Lutonix Catheter
To study pharmacokinetics of intravenously and intraperitoneally administered bevacizumab in patients with malignant ascites for whom there is no systemic anti-tumour treatment available.
The primary objective is to assess the feasibility, safety and efficacy of Lutonix Catheter for treatment of de novo coronary artery stenosis using two distinct treatment strategies: Lutonix Catheter before or after BMS
To identify biological effects of bevacizumab therapy and to visualize distribution kinetics of 111In-bevacizumab with gamma-camera imaging.
Primary objectives:The primary objectives are to evaluate the feasibility of oral administration of bevacizumab-800CW and cetuximab-800CW for detection of neoplasia in BE patients compared to HD-WLE to shorten the qFME procedure and test whether…
The purpose of this Safety Lead In study is to explore if encorafenib and cetuximab in combination with a chemotherapy regimen (either mFOLFOX6 or FOLFIRI) are safe and have beneficial effects on you and your colorectal cancer. This is a small…
The aim of this study is to investigate the safety and efficacy of biodegradable self-expandable stents in patients with a benign fibrotic pancreatic duct stricture due to chronic pancreatitis.
EFFICACY OBJECTIVESWithin each cohort, the study has the following co-primary efficacy objectives:· Assessing early efficacy during the Maintenance Treatment Phase based on a 20%reduction in tumour size after 2 months of treatment· Evaluating PFSThe…
To assess the effect of MEDI4736 in combination with olaparib±bevacizumab in patients with selected advanced solid tumors.To assess the safety and tolerability of MEDI4736 in combination with olaparib (±bevacizumab) in patients with selected…